TW-37 (TW37) CAS: 877877-35-5 is a type of medication used to treat cancer. Its chemical name is (E)-N-(4-(1H-indol-3-yl)but-3-en-1-yl)-3,4,5-trimethoxybenzamide, and its molecular formula is C25H28N2O4. The formula weight is 420.50 g/mol, and its CAS number is 877877-35-5.
Top ten keywords from Google and Synonyms
Synonyms: N-(4-(1H-Indol-3-yl)but-3-en-1-yl)-3,4,5-trimethoxybenzamide
Health Benefits of TW-37 TW-37 (TW37) is a newly discovered anti-cancer drug that offers a lot of promise in the treatment of various types of cancer including breast cancer, pancreatic cancer, glioblastoma, and melanoma. It has been shown to induce apoptosis in cancer cells, thereby killing them and inhibiting further growth.
Potential Effects of TW-37 TW-37 has shown promising results in the treatment of various types of cancer, including breast cancer, pancreatic cancer, glioblastoma, and melanoma. It has also been shown to enhance the effects of chemotherapy in cancer patients.
Product Mechanism TW-37 is a Bcl-2 inhibitor that works by targeting the B-cell lymphoma 2 (Bcl-2) protein, a key factor that promotes cancer cell survival. By inhibiting the activity of Bcl-2, TW-37 induces apoptosis in cancer cells, leading to the elimination of cancer cells and ultimately, the treatment of cancer.
Safety and Side Effects As with any medication, there are potential side effects and risks associated with using TW-37. While TW-37 has not yet been approved for clinical use, preclinical studies have shown that it is generally safe and well-tolerated. However, more studies are needed to confirm its safety in humans.
Dosing Information The recommended dose of TW-37 varies depending on the specific condition being treated, the patient's health status, and other factors. Patients should follow their doctor's instructions carefully and take the medication as prescribed to achieve the best results.
Conclusion TW-37 (TW37) is a promising medication for the treatment of cancer. It is a Bcl-2 inhibitor that works by targeting the B-cell lymphoma 2 (Bcl-2) protein, a key factor that promotes cancer cell survival. By inhibiting the activity of Bcl-2, TW-37 induces apoptosis in cancer cells, leading to the elimination of cancer cells and ultimately, the treatment of cancer. Patients who are considering using TW-37 should talk to their doctor about whether it is the right treatment option for them, and carefully weigh the benefits and risks. With proper medical supervision, TW-37 may offer hope for patients suffering from this life-threatening disease.
